Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mesoblast

11.69
-0.0800-0.68%
Post-market: 11.27-0.4182-3.58%19:09 EDT
Volume:98.47K
Turnover:1.15M
Market Cap:1.49B
PE:-12.67
High:11.85
Open:11.71
Low:11.61
Close:11.77
Loading ...

Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US

MT Newswires Live
·
17 Apr

Mesoblast Expands Ryoncil Coverage to Over 100 Million US Lives

TIPRANKS
·
17 Apr

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

GlobeNewswire
·
17 Apr

Mesoblast Limited Announces Cessation of Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Issues Over 8 Million New Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Announces Quotation of New Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Issues New Equity Securities Under Employee Incentive Scheme

TIPRANKS
·
14 Apr

Mesoblast Limited Issues New Equity Securities for Employee Incentive

TIPRANKS
·
08 Apr

Top broker says Mesoblast shares can rocket 100%

MotleyFool
·
08 Apr

Mesoblast Considers Ryoncil, Revascor to Be US-Origin Products

MT Newswires Live
·
04 Apr

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

The Market Herald
·
04 Apr

Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025

The Market Herald
·
04 Apr

BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs

Reuters
·
04 Apr

Mesoblast Says Products Exempt From US Tariffs

MT Newswires Live
·
04 Apr

BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs

Reuters
·
04 Apr

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

THOMSON REUTERS
·
04 Apr

Mesoblast Ltd - Cell Therapy Products Not Subject to U.S. Tariffs

THOMSON REUTERS
·
04 Apr

Mesoblast - Allogeneic Cellular Products, Including Ryoncil and Revascor, Will Not Be Subject to Tariffs

THOMSON REUTERS
·
04 Apr

Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate

MT Newswires Live
·
03 Apr

Mesoblast Seeks US FDA Meeting to Discuss Approval for Heart Failure Drug Candidate

MT Newswires Live
·
03 Apr